The development of anesthetic cream (EMLA) taping technique for reducing pain from pretarsal botulinum toxin A injection in hemifacial spasm

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240913006

Enrollment

Registered

2024-09-13

Start date

2024-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemifacial spasm Hemifacial spasm, Botulinum toxin, Anesthetic tape

Interventions

Anesthetic cream tape : 5%Emla cream,Cream base

Experimental Drug,Placebo Comparator Drug

Anesthetic cream tape,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Hemifacial spasm patients who can control disease with 3 point BoNT injection Written informed consent

Exclusion criteria

Exclusion criteria: Allergy to all anesthetic drugs Acute inflammation of skin (area of treatment) Acute ocular surface disease

Design outcomes

Primary

Measure	Time frame
pain score 30 minutes Visual analogue scale	—

Secondary

Measure	Time frame
Satisfaction score 30 minutes Visual analogue scale,Complication 30 minutes percent	—

Countries

Thailand

Contacts

Public ContactAkarawit Eiamsamarng

Faculty of Medicine Siriraj Hospital, Mahidol University

akarawit.eia@mahidol.ac.th0929299259

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026